Covington Represents Sanofi on AI Drug Discovery Collaboration Worth Up To 5 2 Billion

NEW YORK—Covington represented Sanofi in its research collaboration and license agreement to develop up to 15 novel small molecule candidates across oncology and immunology with Exscientia. Under the terms of the agreement, Exscientia will receive an upfront cash payment of $100 million from Sanofi and will be eligible to receive future research, translational, clinical development, regulatory, and commercial milestone payments of up to approximately $5.2 billion in aggregate, if all milestones for all programs are achieved.

Sanofi is dedicated to supporting people through their health challenges. Sanofi is a global biopharmaceutical company focused on human health, preventing illness with vaccines, providing innovative treatments to fight pain and ease suffering.

Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner.

The Covington team was led by Jeremy Hutcher and Ying Zhao.